Synergistic effects of two naturally occurring iridoids in eliciting a rapid antidepressant action by up-regulating hippocampal PACAP signalling

Br J Pharmacol. 2022 Aug;179(16):4078-4091. doi: 10.1111/bph.15847. Epub 2022 Apr 22.

Abstract

Background and purpose: Current mainstream antidepressants have limited efficacy with a delayed onset of action. Yueju, a herbal medicine, has a rapid antidepressant action. Identification of the active ingredients in Yueju and the mechanism/s involved was carried out.

Experimental approach: Key molecule/s and compounds involved in this antidepressant action was identified by transcriptomic and HPLC analysis, respectively. Antidepressant effects were evaluated using various behavioural experiments. The signalling involved was assessed using site-directed pharmacological intervention or optogenetic manipulation.

Key results: Transcriptomic analysis showed that Yueju up-regulated pituitary adenylate cyclase activating polypeptide (PACAP) expression in the hippocampus. Two iridoids, geniposide and shanzhiside methyl ester, were identified and quantified from Yueju. Only co-treatment with both, at an equivalent concentrations found in Yueju, increased PACAP expression and elicited a rapid antidepressant action, which were blocked by intra-dentate gyrus infusion of a PACAP antagonist or optogenetic inactivation of PACAP expressing neurons. Geniposide and shanzhiside methyl ester co-treatment rapidly inhibited CaMKII phosphorylation and enhanced mTOR/4EBP1/P70S6k/BDNF ignalling, while intra-dentate gyrus infusions of a CaMKII activator blunted the rapid antidepressant action and BDNF expression up-regulation induced by the co-treatment. A single co-treatment of them rapidly improved depression-like behaviours and up-regulated hippocampal PACAP signalling in the repeated corticosterone-induced depression model, further confirming the involvement of PACAP.

Conclusion and implications: Geniposide and shanzhiside methyl ester co-treatment had a synergistic rapid onset antidepressant action by triggering hippocampal PACAP activity and associated CaMKII-BDNF signalling. This mechanism could be targeted for development of fast onset antidepressants.

Keywords: BDNF; CaMKII; PACAP; novelty-suppressed feeding test; rapid antidepressant; synergism.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antidepressive Agents / therapeutic use
  • Brain-Derived Neurotrophic Factor* / metabolism
  • Calcium-Calmodulin-Dependent Protein Kinase Type 2 / metabolism
  • Calcium-Calmodulin-Dependent Protein Kinase Type 2 / pharmacology
  • Esters / metabolism
  • Esters / pharmacology
  • Hippocampus
  • Iridoids / metabolism
  • Iridoids / pharmacology
  • Pituitary Adenylate Cyclase-Activating Polypeptide* / metabolism
  • Pituitary Adenylate Cyclase-Activating Polypeptide* / pharmacology

Substances

  • Antidepressive Agents
  • Brain-Derived Neurotrophic Factor
  • Esters
  • Iridoids
  • Pituitary Adenylate Cyclase-Activating Polypeptide
  • Calcium-Calmodulin-Dependent Protein Kinase Type 2